Patient characteristics
Patient no. . | Age, y . | Sex . | Race . | > CTC grade 2 protocol-related adverse event . |
---|---|---|---|---|
P1 | 60 | Female | White | Grade 3 urticaria* |
P2 | 65 | Male | White | None |
P3 | 67 | Female | White | None |
P4 | 66 | Male | White | None |
P5 | 73 | Male | White | None |
P6 | 62 | Male | Hispanic | None |
Patient no. . | Age, y . | Sex . | Race . | > CTC grade 2 protocol-related adverse event . |
---|---|---|---|---|
P1 | 60 | Female | White | Grade 3 urticaria* |
P2 | 65 | Male | White | None |
P3 | 67 | Female | White | None |
P4 | 66 | Male | White | None |
P5 | 73 | Male | White | None |
P6 | 62 | Male | Hispanic | None |
CTC indicates Common Toxicity Criteria; and DC, dendritic cell.
Related to lenalidomide as it preceded DC vaccine.